Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01616
|
|||||
| Drug Name |
Cholyl lysyl fluorescein
|
|||||
| Indication | Hepatitis virus infection [ICD11: 1E5Z] | Phase 2 | [1] | |||
| Formula |
C51H63N3O11S
|
|||||
| Canonical SMILES |
CC(CCC(=O)NC(CCCCNC(=S)NC1=CC(=C(C=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O)C(=O)O)C5CCC6C5(C(CC7C6C(CC8C7(CCC(C8)O)C)O)O)C
|
|||||
| InChI |
InChI=1S/C51H63N3O11S/c1-26(36-14-15-37-46-38(25-43(59)51(36,37)3)50(2)18-17-31(57)20-27(50)21-40(46)58)7-16-44(60)54-39(48(63)64)6-4-5-19-52-49(66)53-28-8-11-32(35(22-28)47(61)62)45-33-12-9-29(55)23-41(33)65-42-24-30(56)10-13-34(42)45/h8-13,22-24,26-27,31,36-40,43,46,55,57-59H,4-7,14-21,25H2,1-3H3,(H,54,60)(H,61,62)(H,63,64)(H2,52,53,66)/t26-,27+,31-,36-,37+,38+,39+,40-,43+,46+,50+,51-/m1/s1
|
|||||
| InChIKey |
ZUJFMZPBQQCXQR-TZCNZRNCSA-N
|
|||||
| Pharmaceutical Properties | Molecular Weight | 926.1 | Topological Polar Surface Area | 267 | ||
| Heavy Atom Count | 66 | Rotatable Bond Count | 14 | |||
| Hydrogen Bond Donor Count | 9 | Hydrogen Bond Acceptor Count | 12 | |||
| XLogP |
5.9
|
|||||
| PubChem CID | ||||||
| DT(s) Transporting This Drug | MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00915057) Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972. | |||||
| 2 | The emerging role of transport systems in liver function tests. Eur J Pharmacol. 2012 Jan 30;675(1-3):1-5. | |||||
| 3 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.